Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 4/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 4/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5742902 | 1.00 | ATM (0.60) | ATMTSHRSYKAPPACE | |
| SCHEMBL597848 | 0.93 | CTSS (0.53) | ATMTSHRSYKAPPACE | |
| SCHEMBL597847 | 0.93 | CTSS (0.53) | ATMTSHRSYKAPPACE | |
| SCHEMBL23168374 | 0.90 | ATM (0.65) | ATMTSHRSYKAPPACE | |
| SCHEMBL5408401 | 0.90 | ATM (0.65) | ATMTSHRSYKAPPACE | |
| SCHEMBL5408407 | 0.90 | ATM (0.65) | ATMTSHRSYKAPPACE | |
| SCHEMBL21214797 | 0.89 | CTSK (0.49) | ATMTSHRSYKAPPACE | |
| SCHEMBL16232045 | 0.88 | ATM (0.62) | ATMTSHRSYKAPPACE | |
| SCHEMBL18262766 | 0.87 | ATM (0.46) | ATMTSHRCTSK | |
| SCHEMBL5411669 | 0.86 | ATM (0.67) | ATMSYKAPPACECTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223814-A1 | Nk-2 antagonist basic linear compounds and formulations containing them | MENARINI RICERCHE S.P.A. (IT) | 2006-10-05 | — | — | US | disclosed |
| EP-1620432-A1 | NK-2 ANTAGONIST BASIC LINEAR COMPOUNDS AND FORMULATIONS CONTAINING THEM | Menarini Ricerche S.p.A. (IT) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004094412-A1 | NK-2 ANTAGONIST BASIC LINEAR COMPOUNDS AND FORMULATIONS CONTAINING THEM | MENARINI RICERCHE S.P.A. (IT) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223814-A1 | Nk-2 antagonist basic linear compounds and formulations containing them | BDKRB2, KLK2, BDKRB1 | ATM 2561/4885TSHR 1012/4885SYK 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.